SU 9516

Key Product Details

Product Description

SU 9516 is a cyclin-dependent kinase (cdk) inhibitor (reported IC₅₀ values are 0.02 - 0.03, 0.04 - 0.2, 0.2 - 1.7 and 0.9 μM for cdk2, cdk1, cdk4 and cdk9, respectively). Inhibits pRb phosphorylation causing enhanced pRB/E2F complex formation and induces G1 and G2-M cell cycle arrest. Transcriptionally downregulates Mcl-1 and has antiproliferative, cytostatic and pro-apoptotic effects in vitro.

Product Specifications for SU 9516

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for SU 9516

The following data is based on the product molecular weight 241.25.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	4.15 mL	20.73 mL	41.45 mL
5 mM	0.83 mL	4.15 mL	8.29 mL
10 mM	0.41 mL	2.07 mL	4.15 mL
50 mM	0.08 mL	0.41 mL	0.83 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Jorda How selective are pharmacological inhibitors of cell-cycle-regulating cyclin-dependent kinases? J.Med.Chem 2018 PMID: 30234987
• Yu SU9516, a cyclin-dependent kinase 2 inhibitor, promotes accumulation of high molecular weight E2F complexes in human colon carcinoma cells. Biochem.Pharmacol. 2002 PMID: 12234612
• Gao The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-Imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional m Mol.Pharmacol. 2006 PMID: 16672643
• Lane A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res. 2001 PMID: 11507069

Product Documents for SU 9516